These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2344 related articles for article (PubMed ID: 19539098)

  • 21. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes.
    Reimer T; Hohberg C; Pfützner AH; Jørgensen C; Jensen KH; Pfützner A
    Clin Ther; 2008 Dec; 30(12):2252-62. PubMed ID: 19167585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system.
    Overland J; Molyneaux L; Tewari S; Fatouros R; Melville P; Foote D; Wu T; Yue DK
    Diabetes Obes Metab; 2009 May; 11(5):460-3. PubMed ID: 19236441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
    Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device.
    Landau Z; Klonoff D; Nayberg I; Feldman D; Levit SB; Lender D; Mosenzon O; Raz I; Wainstein J
    Diabetes Metab Res Rev; 2014 Nov; 30(8):686-92. PubMed ID: 24610683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of efficiency of insulin suppository formulations containing sodium salicylate or sodium cholate in insulin dependent diabetic patients.
    Hosny EA; Al-Marzouki ZM; Metwally ME; Souaida MY; Alshaik AR
    Boll Chim Farm; 2003 Oct; 142(8):361-6. PubMed ID: 15040468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
    Radermecker RP; Scheen AJ
    Diabetes Metab Res Rev; 2004; 20(3):178-88. PubMed ID: 15133748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy.
    Sahin SB; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C
    Acta Diabetol; 2010 Dec; 47(4):325-30. PubMed ID: 20842389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.
    Parkner T; Møller MK; Chen JW; Laursen T; Jørgensen C; Smedegaard JS; Lauritzen T; Christiansen JS
    Diabetes Obes Metab; 2008 Jul; 10(7):556-63. PubMed ID: 17593233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of thorough mastication on postprandial plasma glucose concentrations in nonobese Japanese subjects.
    Suzuki H; Fukushima M; Okamoto S; Takahashi O; Shimbo T; Kurose T; Yamada Y; Inagaki N; Seino Y; Fukui T
    Metabolism; 2005 Dec; 54(12):1593-9. PubMed ID: 16311091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
    Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
    Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 118.